ORVATEN Drug Patent Profile
✉ Email this page to a colleague
When do Orvaten patents expire, and when can generic versions of Orvaten launch?
Orvaten is a drug marketed by Upsher Smith Labs and is included in one NDA.
The generic ingredient in ORVATEN is midodrine hydrochloride. There are thirteen drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the midodrine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Orvaten
A generic version of ORVATEN was approved as midodrine hydrochloride by MYLAN PHARMS INC on September 10th, 2003.
Summary for ORVATEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 88 |
| Clinical Trials: | 1 |
| Patent Applications: | 285 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ORVATEN at DailyMed |
Recent Clinical Trials for ORVATEN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| The Craig H. Neilsen Foundation | Phase 4 |
| James J. Peters Veterans Affairs Medical Center | Phase 4 |
Pharmacology for ORVATEN
| Drug Class | alpha-Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha-Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for ORVATEN
US Patents and Regulatory Information for ORVATEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | ORVATEN | midodrine hydrochloride | TABLET;ORAL | 076725-001 | Nov 3, 2004 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Upsher Smith Labs | ORVATEN | midodrine hydrochloride | TABLET;ORAL | 076725-002 | Nov 3, 2004 | AB | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Upsher Smith Labs | ORVATEN | midodrine hydrochloride | TABLET;ORAL | 076725-003 | Nov 3, 2004 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
